Legacy Cost: Takeda’s Entyvio Development Shaped By Tysabri Fallout
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The specter of Tysabri and its restrictive REMS loomed over the review of Takeda’s Entyvio, making for an unusually high level of communication and discussion from Phase II until late in the review cycle – a tally that includes 14 pre-BLA face-to-face meetings between FDA and the sponsor, as well as two advisory committee reviews and two turns before FDA’s REMS Oversight Committee.
You may also be interested in...
Review Of Reviews: Drug Review Profiles 2014
Pharmaceutical Approvals Monthly’s Drug Review Profile stories from 2014.
Review Of Reviews: Drug Review Profiles 2014
Pharmaceutical Approvals Monthly’s Drug Review Profile stories from 2014.
Biogen Idec Suggests PML Risk Manageable For Tecfidera, After Reporting First Case
Biogen Idec noted that 100,000 patients have been treated with the drug since launch and emphasized that the only reported PML case occurred in a patient on long-term treatment despite having a known risk factor.